BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19948914)

  • 21. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
    Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.
    Woenckhaus M; Klein-Hitpass L; Grepmeier U; Merk J; Pfeifer M; Wild P; Bettstetter M; Wuensch P; Blaszyk H; Hartmann A; Hofstaedter F; Dietmaier W
    J Pathol; 2006 Oct; 210(2):192-204. PubMed ID: 16915569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.
    Tsao AS; McDonnell T; Lam S; Putnam JB; Bekele N; Hong WK; Kurie JM
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):660-4. PubMed ID: 12869408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
    Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
    Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers.
    Dosaka-Akita H; Hommura F; Fujita H; Kinoshita I; Nishi M; Morikawa T; Katoh H; Kawakami Y; Kuzumaki N
    Cancer Res; 1998 Jan; 58(2):322-7. PubMed ID: 9443412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Lord RV; Groshen S; Tsao-Wei DD; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2002 Feb; 8(2):438-43. PubMed ID: 11839661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
    Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
    Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
    Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
    Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.
    Marchetti A; Bertacca G; Buttitta F; Chella A; Quattrocolo G; Angeletti CA; Bevilacqua G
    Clin Cancer Res; 1999 Aug; 5(8):2077-81. PubMed ID: 10473089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.
    Wigle DA; Jurisica I; Radulovich N; Pintilie M; Rossant J; Liu N; Lu C; Woodgett J; Seiden I; Johnston M; Keshavjee S; Darling G; Winton T; Breitkreutz BJ; Jorgenson P; Tyers M; Shepherd FA; Tsao MS
    Cancer Res; 2002 Jun; 62(11):3005-8. PubMed ID: 12036904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.